Posted by Michael Wonder on 09 Aug 2021
Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy
5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and at the same time decided that the quality assurance requirements for the treatment of B-cell neoplasms with CAR-T cells are to be applied.
In the future, these high quality standards will apply to medical facilities that want to use Tecartus.
